Equities researchers at Deutsche Bank started coverage on shares of CVS Health (NYSE:CVS) in a research report issued on Thursday, BenzingaRatingsTable reports. The brokerage set a “buy” rating and a $91.00 price target on the pharmacy operator’s stock. Deutsche Bank’s target price indicates a potential upside of 42.21% from the stock’s previous close.
Other equities research analysts also recently issued reports about the stock. Cowen restated an “outperform” rating and set a $76.00 price objective (up from $69.00) on shares of CVS Health in a research report on Tuesday, August 27th. TheStreet upgraded shares of CVS Health from a “c+” rating to a “b-” rating in a report on Monday. Mizuho set a $71.00 price objective on shares of CVS Health and gave the company a “buy” rating in a report on Wednesday, June 5th. ValuEngine downgraded shares of CVS Health from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. Finally, Morgan Stanley reiterated a “buy” rating and issued a $74.00 target price on shares of CVS Health in a research note on Sunday, August 11th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. CVS Health currently has a consensus rating of “Buy” and a consensus target price of $75.87.
NYSE CVS opened at $63.99 on Thursday. CVS Health has a twelve month low of $51.72 and a twelve month high of $82.15. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.64 and a current ratio of 0.95. The stock has a market capitalization of $82.82 billion, a PE ratio of 9.04, a P/E/G ratio of 1.39 and a beta of 0.85. The stock has a 50-day simple moving average of $59.26 and a 200 day simple moving average of $55.85.
CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.19. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. The firm had revenue of $63.43 billion for the quarter, compared to the consensus estimate of $62.66 billion. During the same quarter in the prior year, the business earned $1.69 EPS. The business’s revenue for the quarter was up 35.2% compared to the same quarter last year. As a group, equities research analysts forecast that CVS Health will post 6.96 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bay Harbor Wealth Management LLC boosted its position in CVS Health by 1,871.4% during the first quarter. Bay Harbor Wealth Management LLC now owns 552 shares of the pharmacy operator’s stock valued at $30,000 after purchasing an additional 524 shares during the last quarter. Centaurus Financial Inc. grew its stake in shares of CVS Health by 570.8% in the 1st quarter. Centaurus Financial Inc. now owns 1,630 shares of the pharmacy operator’s stock valued at $30,000 after purchasing an additional 1,387 shares during the period. Manchester Financial Inc. bought a new stake in shares of CVS Health in the 2nd quarter valued at approximately $31,000. Hudock Capital Group LLC grew its position in CVS Health by 54.0% during the 2nd quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 202 shares during the last quarter. Finally, Executive Wealth Management LLC grew its position in CVS Health by 62.4% during the 2nd quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 217 shares during the last quarter. Institutional investors and hedge funds own 76.06% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Read More: What causes a stock to be most active?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.